메뉴 건너뛰기




Volumn 36, Issue 1, 2015, Pages 3-16

Combination antibiotic treatment of serious methicillin-resistant staphylococcus aureus infections

Author keywords

combination antibiotic therapy; daptomycin; methicillin resistant Staphylococcus aureus; vancomycin

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFAZOLIN; CEFTAROLINE; CEFTOBIPROLE; CEFTRIAXONE; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; FOSFOMYCIN; GENTAMICIN; IMIPENEM; LINEZOLID; MEROPENEM; NAFCILLIN; ORITAVANCIN; OXACILLIN; RIFAMPICIN; TELAVANCIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; VANCOMYCIN;

EID: 84964284880     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0034-1396906     Document Type: Article
Times cited : (87)

References (155)
  • 1
    • 77951163712 scopus 로고    scopus 로고
    • Staphylococcus aureus bacteraemia: A major cause of mortality in Australia and New Zealand
    • Australia New Zealand Cooperative on Outcomes in Staphylococcal Sepsis
    • Turnidge J. D.; Kotsanas D.; Munckhof W.; et al. Australia New Zealand Cooperative on Outcomes in Staphylococcal Sepsis. Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New Zealand. Med J Aust: 2009; 191 7 368 373
    • (2009) Med J Aust , vol.191 , Issue.7 , pp. 368-373
    • Turnidge, J.D.1    Kotsanas, D.2    Munckhof, W.3
  • 2
    • 84888990813 scopus 로고    scopus 로고
    • National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011
    • Emerging Infections Program-Active Bacterial Core Surveillance MRSA Surveillance Investigators
    • Dantes R.; Mu Y.; Belflower R.; et al. Emerging Infections Program-Active Bacterial Core Surveillance MRSA Surveillance Investigators. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern Med: 2013; 173 21 1970 1978
    • (2013) JAMA Intern Med , vol.173 , Issue.21 , pp. 1970-1978
    • Dantes, R.1    Mu, Y.2    Belflower, R.3
  • 3
    • 78049512867 scopus 로고    scopus 로고
    • Methicillin-resistant Staphylococcus aureus (MRSA): Burden of disease and control challenges in Europe
    • Köck R.; Becker K.; Cookson B.; et al. Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveill: 2010; 15 41 19688
    • (2010) Euro Surveill , vol.15 , Issue.41 , pp. 19688
    • Köck, R.1    Becker, K.2    Cookson, B.3
  • 4
    • 79951844269 scopus 로고    scopus 로고
    • Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children
    • Liu C.; Bayer A.; Cosgrove S. E.; et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis: 2011; 52 e18 55
    • (2011) Clin Infect Dis , vol.52 , pp. e18-55
    • Liu, C.1    Bayer, A.2    Cosgrove, S.E.3
  • 5
    • 33747365321 scopus 로고    scopus 로고
    • Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus
    • S. aureus Endocarditis and Bacteremia Study Group
    • Fowler V. G. Jr, Boucher H. W.; Corey G. R.; et al. S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med: 2006; 355 7 653 665
    • (2006) N Engl J Med , vol.355 , Issue.7 , pp. 653-665
    • Fowler, G.V.1    Boucher, H.W.2    Corey, G.R.3
  • 6
    • 58749115917 scopus 로고    scopus 로고
    • Complicated skin and skin-structure infections and catheter-related bloodstream infections: Noninferiority of linezolid in a phase 3 study
    • Wilcox M. H.; Tack K. J.; Bouza E.; et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis: 2009; 48 2 203 212
    • (2009) Clin Infect Dis , vol.48 , Issue.2 , pp. 203-212
    • Wilcox, M.H.1    Tack, K.J.2    Bouza, E.3
  • 7
    • 84856937734 scopus 로고    scopus 로고
    • Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: A randomized, controlled study
    • Wunderink R. G.; Niederman M. S.; Kollef M. H.; et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis: 2012; 54 5 621 629
    • (2012) Clin Infect Dis , vol.54 , Issue.5 , pp. 621-629
    • Wunderink, R.G.1    Niederman, M.S.2    Kollef, M.H.3
  • 8
    • 0029819239 scopus 로고    scopus 로고
    • In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis
    • Mulazimoglu L.; Drenning S. D.; Yu V. L. In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother: 1996; 40 10 2428 2430
    • (1996) Antimicrob Agents Chemother , vol.40 , Issue.10 , pp. 2428-2430
    • Mulazimoglu, L.1    Drenning, S.D.2    Yu, V.L.3
  • 9
    • 0037392688 scopus 로고    scopus 로고
    • In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods
    • Jacqueline C.; Caillon J.; Le Mabecque V.; et al. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J Antimicrob Chemother: 2003; 51 4 857 864
    • (2003) J Antimicrob Chemother , vol.51 , Issue.4 , pp. 857-864
    • Jacqueline, C.1    Caillon, J.2    Le Mabecque, V.3
  • 10
    • 12244270396 scopus 로고    scopus 로고
    • In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus
    • Grohs P.; Kitzis M. D.; Gutmann L. In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus. Antimicrob Agents Chemother: 2003; 47 1 418 420
    • (2003) Antimicrob Agents Chemother , vol.47 , Issue.1 , pp. 418-420
    • Grohs, P.1    Kitzis, M.D.2    Gutmann, L.3
  • 11
    • 70349330330 scopus 로고    scopus 로고
    • In vitro 24-hour time-kill studies of vancomycin and linezolid in combination versus methicillin-resistant Staphylococcus aureus
    • Singh S. R.; Bacon A. E. III, Young D. C.; Couch K. A. In vitro 24-hour time-kill studies of vancomycin and linezolid in combination versus methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother: 2009; 53 10 4495 4497
    • (2009) Antimicrob Agents Chemother , vol.53 , Issue.10 , pp. 4495-4497
    • Singh, S.R.1    Bacon, E.A.2    Young, D.C.3    Couch, K.A.4
  • 12
    • 0036276212 scopus 로고    scopus 로고
    • AZD2563, a new oxazolidinone: Bactericidal activity and synergy studies combined with gentamicin or vancomycin against staphylococci and streptococcal strains
    • Jones R. N.; Anderegg T. R.; Deshpande L. M. AZD2563, a new oxazolidinone: bactericidal activity and synergy studies combined with gentamicin or vancomycin against staphylococci and streptococcal strains. Diagn Microbiol Infect Dis: 2002; 43 1 87 90
    • (2002) Diagn Microbiol Infect Dis , vol.43 , Issue.1 , pp. 87-90
    • Jones, R.N.1    Anderegg, T.R.2    Deshpande, L.M.3
  • 13
    • 0042423638 scopus 로고    scopus 로고
    • Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus
    • Chiang F. Y.; Climo M. Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother: 2003; 47 9 3002 3004
    • (2003) Antimicrob Agents Chemother , vol.47 , Issue.9 , pp. 3002-3004
    • Chiang, F.Y.1    Climo, M.2
  • 14
    • 0034425537 scopus 로고    scopus 로고
    • Linezolid therapy of Staphylococcus aureus experimental osteomyelitis
    • Patel R.; Piper K. E.; Rouse M. S.; Steckelberg J. M. Linezolid therapy of Staphylococcus aureus experimental osteomyelitis. Antimicrob Agents Chemother: 2000; 44 12 3438 3440
    • (2000) Antimicrob Agents Chemother , vol.44 , Issue.12 , pp. 3438-3440
    • Patel, R.1    Piper, K.E.2    Rouse, M.S.3    Steckelberg, J.M.4
  • 15
    • 0942279622 scopus 로고    scopus 로고
    • Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression
    • Bernardo K.; Pakulat N.; Fleer S.; et al. Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob Agents Chemother: 2004; 48 2 546 555
    • (2004) Antimicrob Agents Chemother , vol.48 , Issue.2 , pp. 546-555
    • Bernardo, K.1    Pakulat, N.2    Fleer, S.3
  • 16
    • 33846161259 scopus 로고    scopus 로고
    • Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus
    • Stevens D. L.; Ma Y.; Salmi D. B.; McIndoo E.; Wallace R. J.; Bryant A. E. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis: 2007; 195 2 202 211
    • (2007) J Infect Dis , vol.195 , Issue.2 , pp. 202-211
    • Stevens, D.L.1    Ma, Y.2    Salmi, D.B.3    McIndoo, E.4    Wallace, R.J.5    Bryant, A.E.6
  • 17
    • 33144483679 scopus 로고    scopus 로고
    • Successful treatment of staphylococcal toxic shock syndrome with linezolid: A case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics
    • Stevens D. L.; Wallace R. J.; Hamilton S. M.; Bryant A. E. Successful treatment of staphylococcal toxic shock syndrome with linezolid: a case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics. Clin Infect Dis: 2006; 42 5 729 730
    • (2006) Clin Infect Dis , vol.42 , Issue.5 , pp. 729-730
    • Stevens, D.L.1    Wallace, R.J.2    Hamilton, S.M.3    Bryant, A.E.4
  • 18
    • 84872858655 scopus 로고    scopus 로고
    • Mechanisms of daptomycin resistance in Staphylococcus aureus: Role of the cell membrane and cell wall
    • Bayer A. S.; Schneider T.; Sahl H. G. Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann N Y Acad Sci: 2013; 1277 139 158
    • (2013) Ann N y Acad Sci , vol.1277 , pp. 139-158
    • Bayer, A.S.1    Schneider, T.2    Sahl, H.G.3
  • 19
    • 84855496122 scopus 로고    scopus 로고
    • Antibiotic Combinations with Daptomycin for Treatment of Staphylococcus aureus Infections
    • Nadrah K.; Strle F. Antibiotic Combinations with Daptomycin for Treatment of Staphylococcus aureus Infections. Chemother Res Pract: 2011; 2011 619321
    • (2011) Chemother Res Pract , vol.2011 , pp. 619321
    • Nadrah, K.1    Strle, F.2
  • 20
    • 33646741453 scopus 로고    scopus 로고
    • An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus
    • Patel J. B.; Jevitt L. A.; Hageman J.; McDonald L. C.; Tenover F. C. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis: 2006; 42 11 1652 1653
    • (2006) Clin Infect Dis , vol.42 , Issue.11 , pp. 1652-1653
    • Patel, J.B.1    Jevitt, L.A.2    Hageman, J.3    McDonald, L.C.4    Tenover, F.C.5
  • 22
    • 79956086972 scopus 로고    scopus 로고
    • Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient-A review of the literature
    • van Hal S. J.; Paterson D. L.; Gosbell I. B. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient-A review of the literature. Eur J Clin Microbiol Infect Dis: 2011; 30 5 603 610
    • (2011) Eur J Clin Microbiol Infect Dis , vol.30 , Issue.5 , pp. 603-610
    • Van Hal, S.J.1    Paterson, D.L.2    Gosbell, I.B.3
  • 23
    • 70349173209 scopus 로고    scopus 로고
    • Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: Facts and assumptions
    • Moise P. A.; North D.; Steenbergen J. N.; Sakoulas G. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect Dis: 2009; 9 10 617 624
    • (2009) Lancet Infect Dis , vol.9 , Issue.10 , pp. 617-624
    • Moise, P.A.1    North, D.2    Steenbergen, J.N.3    Sakoulas, G.4
  • 24
    • 33644655658 scopus 로고    scopus 로고
    • Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus
    • Cui L.; Tominaga E.; Neoh H. M.; Hiramatsu K. Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus. Antimicrob Agents Chemother: 2006; 50 3 1079 1082
    • (2006) Antimicrob Agents Chemother , vol.50 , Issue.3 , pp. 1079-1082
    • Cui, L.1    Tominaga, E.2    Neoh, H.M.3    Hiramatsu, K.4
  • 25
    • 29144464885 scopus 로고    scopus 로고
    • Etest synergy testing of clinical isolates of Staphylococcus aureus demonstrating heterogeneous resistance to vancomycin
    • Tsuji B. T.; Rybak M. J. Etest synergy testing of clinical isolates of Staphylococcus aureus demonstrating heterogeneous resistance to vancomycin. Diagn Microbiol Infect Dis: 2006; 54 1 73 77
    • (2006) Diagn Microbiol Infect Dis , vol.54 , Issue.1 , pp. 73-77
    • Tsuji, B.T.1    Rybak, M.J.2
  • 26
    • 33745038340 scopus 로고    scopus 로고
    • Combination therapy with daptomycin, vancomycin, and rifampin for recurrent, severe bone and prosthetic joint infections involving methicillin-resistant Staphylococcus aureus
    • Antony S. J. Combination therapy with daptomycin, vancomycin, and rifampin for recurrent, severe bone and prosthetic joint infections involving methicillin-resistant Staphylococcus aureus. Scand J Infect Dis: 2006; 38 4 293 295
    • (2006) Scand J Infect Dis , vol.38 , Issue.4 , pp. 293-295
    • Antony, S.J.1
  • 27
    • 0031566835 scopus 로고    scopus 로고
    • Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin
    • Hiramatsu K.; Aritaka N.; Hanaki H.; et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet: 1997; 350 9092 1670 1673
    • (1997) Lancet , vol.350 , Issue.9092 , pp. 1670-1673
    • Hiramatsu, K.1    Aritaka, N.2    Hanaki, H.3
  • 28
    • 67349159744 scopus 로고    scopus 로고
    • Tigecycline in combination with other antimicrobials: A review of in vitro, animal and case report studies
    • Entenza J. M.; Moreillon P. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int J Antimicrob Agents: 2009; 34 1 8.e1 8.e9
    • (2009) Int J Antimicrob Agents , vol.34 , Issue.1 , pp. 8e1-8e9
    • Entenza, J.M.1    Moreillon, P.2
  • 29
    • 84861505966 scopus 로고    scopus 로고
    • Excess deaths associated with tigecycline after approval based on noninferiority trials
    • Prasad P.; Sun J.; Danner R. L.; Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis: 2012; 54 12 1699 1709
    • (2012) Clin Infect Dis , vol.54 , Issue.12 , pp. 1699-1709
    • Prasad, P.1    Sun, J.2    Danner, R.L.3    Natanson, C.4
  • 30
    • 0036896559 scopus 로고    scopus 로고
    • Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination
    • Mercier R. C.; Kennedy C.; Meadows C. Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination. Pharmacotherapy: 2002; 22 12 1517 1523
    • (2002) Pharmacotherapy , vol.22 , Issue.12 , pp. 1517-1523
    • Mercier, R.C.1    Kennedy, C.2    Meadows, C.3
  • 31
    • 32644443249 scopus 로고    scopus 로고
    • In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis
    • Petersen P. J.; Labthavikul P.; Jones C. H.; Bradford P. A. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother: 2006; 57 3 573 576
    • (2006) J Antimicrob Chemother , vol.57 , Issue.3 , pp. 573-576
    • Petersen, P.J.1    Labthavikul, P.2    Jones, C.H.3    Bradford, P.A.4
  • 32
    • 21244449587 scopus 로고    scopus 로고
    • Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model
    • Yin L. Y.; Lazzarini L.; Li F.; Stevens C. M.; Calhoun J. H. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J Antimicrob Chemother: 2005; 55 6 995 1002
    • (2005) J Antimicrob Chemother , vol.55 , Issue.6 , pp. 995-1002
    • Yin, L.Y.1    Lazzarini, L.2    Li, F.3    Stevens, C.M.4    Calhoun, J.H.5
  • 33
    • 60649083601 scopus 로고    scopus 로고
    • Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus
    • Rose W. E.; Poppens P. T. Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus. J Antimicrob Chemother: 2009; 63 3 485 488
    • (2009) J Antimicrob Chemother , vol.63 , Issue.3 , pp. 485-488
    • Rose, W.E.1    Poppens, P.T.2
  • 34
    • 84866393193 scopus 로고    scopus 로고
    • In vitro activity and in vivo efficacy of tigecycline alone and in combination with daptomycin and rifampin against Gram-positive cocci isolated from surgical wound infection
    • Silvestri C.; Cirioni O.; Arzeni D.; et al. In vitro activity and in vivo efficacy of tigecycline alone and in combination with daptomycin and rifampin against Gram-positive cocci isolated from surgical wound infection. Eur J Clin Microbiol Infect Dis: 2012; 31 8 1759 1764
    • (2012) Eur J Clin Microbiol Infect Dis , vol.31 , Issue.8 , pp. 1759-1764
    • Silvestri, C.1    Cirioni, O.2    Arzeni, D.3
  • 35
    • 84867613328 scopus 로고    scopus 로고
    • Activity of linezolid and high-dose daptomycin, alone or in combination, in an in vitro model of Staphylococcus aureus biofilm
    • Parra-Ruiz J.; Bravo-Molina A.; Peña-Monje A.; Hernández-Quero J. Activity of linezolid and high-dose daptomycin, alone or in combination, in an in vitro model of Staphylococcus aureus biofilm. J Antimicrob Chemother: 2012; 67 11 2682 2685
    • (2012) J Antimicrob Chemother , vol.67 , Issue.11 , pp. 2682-2685
    • Parra-Ruiz, J.1    Bravo-Molina, A.2    Peña-Monje, A.3    Hernández-Quero, J.4
  • 36
    • 78649666091 scopus 로고    scopus 로고
    • Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations
    • Steed M. E.; Vidaillac C.; Rybak M. J. Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations. Antimicrob Agents Chemother: 2010; 54 12 5187 5192
    • (2010) Antimicrob Agents Chemother , vol.54 , Issue.12 , pp. 5187-5192
    • Steed, M.E.1    Vidaillac, C.2    Rybak, M.J.3
  • 37
    • 80053905897 scopus 로고    scopus 로고
    • Combination therapy with daptomycin, linezolid, and rifampin as treatment option for MRSA meningitis and bacteremia
    • Kelesidis T.; Humphries R.; Ward K.; Lewinski M. A.; Yang O. O. Combination therapy with daptomycin, linezolid, and rifampin as treatment option for MRSA meningitis and bacteremia. Diagn Microbiol Infect Dis: 2011; 71 3 286 290
    • (2011) Diagn Microbiol Infect Dis , vol.71 , Issue.3 , pp. 286-290
    • Kelesidis, T.1    Humphries, R.2    Ward, K.3    Lewinski, M.A.4    Yang, O.O.5
  • 38
    • 1542744059 scopus 로고    scopus 로고
    • Combining quinupristin/dalfopristin with other agents for resistant infections
    • Brown J.; Freeman B. B. III. Combining quinupristin/dalfopristin with other agents for resistant infections. Ann Pharmacother: 2004; 38 4 677 685
    • (2004) Ann Pharmacother , vol.38 , Issue.4 , pp. 677-685
    • Brown, J.1    Freeman, B.B.2
  • 39
    • 0034878868 scopus 로고    scopus 로고
    • Interactions of quinupristin-dalfopristin with eight other antibiotics as measured by time-kill studies with 10 strains of Staphylococcus aureus for which quinupristin-dalfopristin alone was not bactericidal
    • Fuchs P. C.; Barry A. L.; Brown S. D. Interactions of quinupristin-dalfopristin with eight other antibiotics as measured by time-kill studies with 10 strains of Staphylococcus aureus for which quinupristin-dalfopristin alone was not bactericidal. Antimicrob Agents Chemother: 2001; 45 9 2662 2665
    • (2001) Antimicrob Agents Chemother , vol.45 , Issue.9 , pp. 2662-2665
    • Fuchs, P.C.1    Barry, A.L.2    Brown, S.D.3
  • 40
    • 0036721017 scopus 로고    scopus 로고
    • Efficacies of quinupristin-dalfopristin combined with vancomycin in vitro and in experimental endocarditis due to methicillin-resistant Staphylococcus aureus in relation to cross-resistance to macrolides, lincosamides, and streptogramin B- type antibiotics
    • Pavie J.; Lefort A.; Zarrouk V.; et al. Efficacies of quinupristin-dalfopristin combined with vancomycin in vitro and in experimental endocarditis due to methicillin-resistant Staphylococcus aureus in relation to cross-resistance to macrolides, lincosamides, and streptogramin B- type antibiotics. Antimicrob Agents Chemother: 2002; 46 9 3061 3064
    • (2002) Antimicrob Agents Chemother , vol.46 , Issue.9 , pp. 3061-3064
    • Pavie, J.1    Lefort, A.2    Zarrouk, V.3
  • 41
    • 0345219438 scopus 로고    scopus 로고
    • In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus
    • (Suppl A)
    • Kang S. L.; Rybak M. J. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus. J Antimicrob Chemother: 1997; 39 (Suppl A): 33 39
    • (1997) J Antimicrob Chemother , vol.39 , pp. 33-39
    • Kang, S.L.1    Rybak, M.J.2
  • 42
    • 0029017737 scopus 로고
    • Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model
    • Kang S. L.; Rybak M. J. Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model. Antimicrob Agents Chemother: 1995; 39 7 1505 1511
    • (1995) Antimicrob Agents Chemother , vol.39 , Issue.7 , pp. 1505-1511
    • Kang, S.L.1    Rybak, M.J.2
  • 43
    • 0035991980 scopus 로고    scopus 로고
    • In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model
    • Allen G. P.; Cha R.; Rybak M. J. In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model. Antimicrob Agents Chemother: 2002; 46 8 2606 2612
    • (2002) Antimicrob Agents Chemother , vol.46 , Issue.8 , pp. 2606-2612
    • Allen, G.P.1    Cha, R.2    Rybak, M.J.3
  • 44
    • 0035990005 scopus 로고    scopus 로고
    • Combination of quinupristin/dalfopristin and glycopeptide in severe methicillin-resistant staphylococcal infections failing previous glycopeptide regimens
    • Scotton P. G.; Rigoli R.; Vaglia A. Combination of quinupristin/dalfopristin and glycopeptide in severe methicillin-resistant staphylococcal infections failing previous glycopeptide regimens. Infection: 2002; 30 3 161 163
    • (2002) Infection , vol.30 , Issue.3 , pp. 161-163
    • Scotton, P.G.1    Rigoli, R.2    Vaglia, A.3
  • 45
    • 0036195889 scopus 로고    scopus 로고
    • Synercid plus vancomycin for the treatment of severe methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci infections: Evaluation of 5 cases
    • Sgarabotto D.; Cusinato R.; Narne E.; et al. Synercid plus vancomycin for the treatment of severe methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci infections: evaluation of 5 cases. Scand J Infect Dis: 2002; 34 2 122 126
    • (2002) Scand J Infect Dis , vol.34 , Issue.2 , pp. 122-126
    • Sgarabotto, D.1    Cusinato, R.2    Narne, E.3
  • 46
    • 78149483462 scopus 로고    scopus 로고
    • Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia
    • Paul M.; Kariv G.; Goldberg E.; et al. Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother: 2010; 65 12 2658 2665
    • (2010) J Antimicrob Chemother , vol.65 , Issue.12 , pp. 2658-2665
    • Paul, M.1    Kariv, G.2    Goldberg, E.3
  • 47
    • 84865970452 scopus 로고    scopus 로고
    • Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD
    • Chan K. E.; Warren H. S.; Thadhani R. I.; et al. Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD. J Am Soc Nephrol: 2012; 23 9 1551 1559
    • (2012) J Am Soc Nephrol , vol.23 , Issue.9 , pp. 1551-1559
    • Chan, K.E.1    Warren, H.S.2    Thadhani, R.I.3
  • 48
    • 0141925832 scopus 로고    scopus 로고
    • A prospective multicenter study of Staphylococcus aureus bacteremia: Incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance
    • Chang F. Y.; MacDonald B. B.; Peacock J. E. Jr.; et al. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore): 2003; 82 5 322 332
    • (2003) Medicine (Baltimore) , vol.82 , Issue.5 , pp. 322-332
    • Chang, F.Y.1    Macdonald, B.B.2    Peacock, E.J.3
  • 49
    • 33645082207 scopus 로고    scopus 로고
    • Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia
    • Khatib R.; Saeed S.; Sharma M.; Riederer K.; Fakih M. G.; Johnson L. B. Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis: 2006; 25 3 181 185
    • (2006) Eur J Clin Microbiol Infect Dis , vol.25 , Issue.3 , pp. 181-185
    • Khatib, R.1    Saeed, S.2    Sharma, M.3    Riederer, K.4    Fakih, M.G.5    Johnson, L.B.6
  • 50
    • 80054096461 scopus 로고    scopus 로고
    • Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia
    • Schweizer M. L.; Furuno J. P.; Harris A. D.; et al. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia. BMC Infect Dis: 2011; 11 279
    • (2011) BMC Infect Dis , vol.11 , pp. 279
    • Schweizer, M.L.1    Furuno, J.P.2    Harris, A.D.3
  • 51
    • 35349019173 scopus 로고    scopus 로고
    • Invasive methicillin-resistant Staphylococcus aureus infections in the United States
    • Active Bacterial Core surveillance (ABCs) MRSA Investigators
    • Klevens R. M.; Morrison M. A.; Nadle J.; et al. Active Bacterial Core surveillance (ABCs) MRSA Investigators. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA: 2007; 298 15 1763 1771
    • (2007) JAMA , vol.298 , Issue.15 , pp. 1763-1771
    • Klevens, R.M.1    Morrison, M.A.2    Nadle, J.3
  • 52
    • 40749099031 scopus 로고    scopus 로고
    • Are community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains
    • Popovich K. J.; Weinstein R. A.; Hota B. Are community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains? Clin Infect Dis: 2008; 46 6 787 794
    • (2008) Clin Infect Dis , vol.46 , Issue.6 , pp. 787-794
    • Popovich, K.J.1    Weinstein, R.A.2    Hota, B.3
  • 53
    • 3943093972 scopus 로고    scopus 로고
    • Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study
    • Wisplinghoff H.; Bischoff T.; Tallent S. M.; Seifert H.; Wenzel R. P.; Edmond M. B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis: 2004; 39 3 309 317
    • (2004) Clin Infect Dis , vol.39 , Issue.3 , pp. 309-317
    • Wisplinghoff, H.1    Bischoff, T.2    Tallent, S.M.3    Seifert, H.4    Wenzel, R.P.5    Edmond, M.B.6
  • 54
    • 0026608763 scopus 로고
    • The in-vitro antibacterial activity of a combination of cefpirome or cefoperazone with vancomycin against enterococci and Staphylococcus aureus
    • (Suppl A)
    • Seibert G.; Isert D.; Klesel N.; Limbert M.; Markus A.; Schrinner E. The in-vitro antibacterial activity of a combination of cefpirome or cefoperazone with vancomycin against enterococci and Staphylococcus aureus. J Antimicrob Chemother: 1992; 29 (Suppl A): 25 30
    • (1992) J Antimicrob Chemother , vol.29 , pp. 25-30
    • Seibert, G.1    Isert, D.2    Klesel, N.3    Limbert, M.4    Markus, A.5    Schrinner, E.6
  • 55
    • 0030938582 scopus 로고    scopus 로고
    • An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected fibrin clots
    • Palmer S. M.; Rybak M. J. An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected fibrin clots. J Antimicrob Chemother: 1997; 39 4 515 518
    • (1997) J Antimicrob Chemother , vol.39 , Issue.4 , pp. 515-518
    • Palmer, S.M.1    Rybak, M.J.2
  • 56
    • 0032779486 scopus 로고    scopus 로고
    • Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin
    • Climo M. W.; Patron R. L.; Archer G. L. Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin. Antimicrob Agents Chemother: 1999; 43 7 1747 1753
    • (1999) Antimicrob Agents Chemother , vol.43 , Issue.7 , pp. 1747-1753
    • Climo, M.W.1    Patron, R.L.2    Archer, G.L.3
  • 57
    • 0035186957 scopus 로고    scopus 로고
    • In vitro synergy between cefepime and vancomycin against methicillin-susceptible and -resistant Staphylococcus aureus and Staphylococcus epidermidis
    • Lozniewski A.; Lion C.; Mory F.; Weber M. In vitro synergy between cefepime and vancomycin against methicillin-susceptible and -resistant Staphylococcus aureus and Staphylococcus epidermidis. J Antimicrob Chemother: 2001; 47 1 83 86
    • (2001) J Antimicrob Chemother , vol.47 , Issue.1 , pp. 83-86
    • Lozniewski, A.1    Lion, C.2    Mory, F.3    Weber, M.4
  • 58
    • 0034048698 scopus 로고    scopus 로고
    • Vancomycin and oxacillin synergy for methicillin-resistant staphylococci
    • Domaracki B. E.; Evans A. M.; Venezia R. A. Vancomycin and oxacillin synergy for methicillin-resistant staphylococci. Antimicrob Agents Chemother: 2000; 44 5 1394 1396
    • (2000) Antimicrob Agents Chemother , vol.44 , Issue.5 , pp. 1394-1396
    • Domaracki, B.E.1    Evans, A.M.2    Venezia, R.A.3
  • 59
    • 35349017448 scopus 로고    scopus 로고
    • In vitro evaluation of antibiotics' combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections
    • Drago L.; De Vecchi E.; Nicola L.; Gismondo M. R. In vitro evaluation of antibiotics' combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections. BMC Infect Dis: 2007; 7 111
    • (2007) BMC Infect Dis , vol.7 , pp. 111
    • Drago, L.1    De Vecchi, E.2    Nicola, L.3    Gismondo, M.R.4
  • 60
    • 27644484826 scopus 로고    scopus 로고
    • Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan
    • Kobayashi Y. Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan. J Infect Chemother: 2005; 11 5 259 261
    • (2005) J Infect Chemother , vol.11 , Issue.5 , pp. 259-261
    • Kobayashi, Y.1
  • 61
    • 78449261915 scopus 로고    scopus 로고
    • In vitro and in vivo activities of linezolid alone and combined with vancomycin and imipenem against Staphylococcus aureus with reduced susceptibility to glycopeptides
    • Ribes S.; Pachón-Ibáñez M. E.; Domínguez M. A.; et al. In vitro and in vivo activities of linezolid alone and combined with vancomycin and imipenem against Staphylococcus aureus with reduced susceptibility to glycopeptides. Eur J Clin Microbiol Infect Dis: 2010; 29 11 1361 1367
    • (2010) Eur J Clin Microbiol Infect Dis , vol.29 , Issue.11 , pp. 1361-1367
    • Ribes, S.1    Pachón-Ibáñez, M.E.2    Domínguez, M.A.3
  • 62
    • 75749089192 scopus 로고    scopus 로고
    • Lack of bactericidal antagonism or synergism in vitro between oxacillin and vancomycin against methicillin-susceptible strains of Staphylococcus aureus
    • Joukhadar C.; Pillai S.; Wennersten C.; Moellering R. C. Jr, Eliopoulos G. M. Lack of bactericidal antagonism or synergism in vitro between oxacillin and vancomycin against methicillin-susceptible strains of Staphylococcus aureus. Antimicrob Agents Chemother: 2010; 54 2 773 777
    • (2010) Antimicrob Agents Chemother , vol.54 , Issue.2 , pp. 773-777
    • Joukhadar, C.1    Pillai, S.2    Wennersten, C.3    Moellering, C.R.4    Eliopoulos, G.M.5
  • 63
    • 79851473871 scopus 로고    scopus 로고
    • Evaluation of the synergistic potential of vancomycin combined with other antimicrobial agents against methicillin-resistant Staphylococcus aureus and coagulase-negative Staphylococcus spp strains
    • Silva L. V.; Araújo M. T.; Santos K. R.; Nunes A. P. Evaluation of the synergistic potential of vancomycin combined with other antimicrobial agents against methicillin-resistant Staphylococcus aureus and coagulase-negative Staphylococcus spp strains. Mem Inst Oswaldo Cruz: 2011; 106 1 44 50
    • (2011) Mem Inst Oswaldo Cruz , vol.106 , Issue.1 , pp. 44-50
    • Silva, L.V.1    Araújo, M.T.2    Santos, K.R.3    Nunes, A.P.4
  • 64
    • 84455173055 scopus 로고    scopus 로고
    • In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus
    • Hagihara M.; Wiskirchen D. E.; Kuti J. L.; Nicolau D. P. In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother: 2012; 56 1 202 207
    • (2012) Antimicrob Agents Chemother , vol.56 , Issue.1 , pp. 202-207
    • Hagihara, M.1    Wiskirchen, D.E.2    Kuti, J.L.3    Nicolau, D.P.4
  • 65
    • 84857163362 scopus 로고    scopus 로고
    • Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus
    • Fernandez J.; Abbanat D.; Shang W.; et al. Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother: 2012; 56 3 1476 1484
    • (2012) Antimicrob Agents Chemother , vol.56 , Issue.3 , pp. 1476-1484
    • Fernandez, J.1    Abbanat, D.2    Shang, W.3
  • 66
    • 84864232796 scopus 로고    scopus 로고
    • Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model
    • Leonard S. N. Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model. PLoS ONE: 2012; 7 7 e42103
    • (2012) PLoS ONE , vol.7 , Issue.7 , pp. e42103
    • Leonard, S.N.1
  • 67
    • 84893491165 scopus 로고    scopus 로고
    • Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus Isolates and vancomycin-intermediate S. Aureus isolates in vitro
    • Dilworth T. J.; Sliwinski J.; Ryan K.; Dodd M.; Mercier R. C. Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus Isolates and vancomycin-intermediate S. aureus isolates in vitro. Antimicrob Agents Chemother: 2014; 58 2 1028 1033
    • (2014) Antimicrob Agents Chemother , vol.58 , Issue.2 , pp. 1028-1033
    • Dilworth, T.J.1    Sliwinski, J.2    Ryan, K.3    Dodd, M.4    Mercier, R.C.5
  • 68
    • 84877855965 scopus 로고    scopus 로고
    • Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. Aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: Exploring the seesaw effect
    • Werth B. J.; Steed M. E.; Kaatz G. W.; Rybak M. J. Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the seesaw effect Antimicrob Agents Chemother: 2013; 57 6 2664 2668
    • (2013) Antimicrob Agents Chemother , vol.57 , Issue.6 , pp. 2664-2668
    • Werth, B.J.1    Steed, M.E.2    Kaatz, G.W.3    Rybak, M.J.4
  • 69
    • 84876219942 scopus 로고    scopus 로고
    • Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA
    • Werth B. J.; Vidaillac C.; Murray K. P.; et al. Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA. Antimicrob Agents Chemother: 2013; 57 5 2376 2379
    • (2013) Antimicrob Agents Chemother , vol.57 , Issue.5 , pp. 2376-2379
    • Werth, B.J.1    Vidaillac, C.2    Murray, K.P.3
  • 70
    • 30744452985 scopus 로고    scopus 로고
    • Evaluation of in vitro interaction of daptomycin with gentamicin or beta-lactam antibiotics against Staphylococcus aureus and Enterococci by FIC index and timed-kill curves
    • Snydman D. R.; McDermott L. A.; Jacobus N. V. Evaluation of in vitro interaction of daptomycin with gentamicin or beta-lactam antibiotics against Staphylococcus aureus and Enterococci by FIC index and timed-kill curves. J Chemother: 2005; 17 6 614 621
    • (2005) J Chemother , vol.17 , Issue.6 , pp. 614-621
    • Snydman, D.R.1    McDermott, L.A.2    Jacobus, N.V.3
  • 71
    • 0023889166 scopus 로고
    • In vitro activity of LY146032 against gram-positive bacteria
    • Silva M.; Jacobus N. V.; Gorbach S. L. In vitro activity of LY146032 against gram-positive bacteria. Diagn Microbiol Infect Dis: 1988; 9 2 79 85
    • (1988) Diagn Microbiol Infect Dis , vol.9 , Issue.2 , pp. 79-85
    • Silva, M.1    Jacobus, N.V.2    Gorbach, S.L.3
  • 72
    • 3342957138 scopus 로고    scopus 로고
    • Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus
    • Rand K. H.; Houck H. J. Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother: 2004; 48 8 2871 2875
    • (2004) Antimicrob Agents Chemother , vol.48 , Issue.8 , pp. 2871-2875
    • Rand, K.H.1    Houck, H.J.2
  • 73
    • 84869215998 scopus 로고    scopus 로고
    • β-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives
    • Mehta S.; Singh C.; Plata K. B.; et al. β-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives. Antimicrob Agents Chemother: 2012; 56 12 6192 6200
    • (2012) Antimicrob Agents Chemother , vol.56 , Issue.12 , pp. 6192-6200
    • Mehta, S.1    Singh, C.2    Plata, K.B.3
  • 74
    • 33645099674 scopus 로고    scopus 로고
    • In vitro activity of daptomycin alone and in combination with various antimicrobials against Gram-positive cocci
    • Cilli F.; Aydemir S.; Tunger A. In vitro activity of daptomycin alone and in combination with various antimicrobials against Gram-positive cocci. J Chemother: 2006; 18 1 27 32
    • (2006) J Chemother , vol.18 , Issue.1 , pp. 27-32
    • Cilli, F.1    Aydemir, S.2    Tunger, A.3
  • 75
    • 84908272497 scopus 로고    scopus 로고
    • Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes
    • Barber K. E.; Werth B. J.; Ireland C. E.; et al. Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes. J Antimicrob Chemother: 2014; 69 11 3006 3010
    • (2014) J Antimicrob Chemother , vol.69 , Issue.11 , pp. 3006-3010
    • Barber, K.E.1    Werth, B.J.2    Ireland, C.E.3
  • 76
    • 84873583460 scopus 로고    scopus 로고
    • Evaluation of the combination of daptomycin and nafcillin against vancomycin-intermediate Staphylococcus aureus
    • Leonard S. N.; Rolek K. M. Evaluation of the combination of daptomycin and nafcillin against vancomycin-intermediate Staphylococcus aureus. J Antimicrob Chemother: 2013; 68 3 644 647
    • (2013) J Antimicrob Chemother , vol.68 , Issue.3 , pp. 644-647
    • Leonard, S.N.1    Rolek, K.M.2
  • 77
    • 84866315707 scopus 로고    scopus 로고
    • Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity
    • Rose W. E.; Schulz L. T.; Andes D.; et al. Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity. Antimicrob Agents Chemother: 2012; 56 10 5296 5302
    • (2012) Antimicrob Agents Chemother , vol.56 , Issue.10 , pp. 5296-5302
    • Rose, W.E.1    Schulz, L.T.2    Andes, D.3
  • 78
    • 84901251282 scopus 로고    scopus 로고
    • Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations
    • Werth B. J.; Barber K. E.; Ireland C. E.; Rybak M. J. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. Antimicrob Agents Chemother: 2014; 58 6 3177 3181
    • (2014) Antimicrob Agents Chemother , vol.58 , Issue.6 , pp. 3177-3181
    • Werth, B.J.1    Barber, K.E.2    Ireland, C.E.3    Rybak, M.J.4
  • 79
    • 84872041928 scopus 로고    scopus 로고
    • Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model
    • Werth B. J.; Sakoulas G.; Rose W. E.; Pogliano J.; Tewhey R.; Rybak M. J. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother: 2013; 57 1 66 73
    • (2013) Antimicrob Agents Chemother , vol.57 , Issue.1 , pp. 66-73
    • Werth, B.J.1    Sakoulas, G.2    Rose, W.E.3    Pogliano, J.4    Tewhey, R.5    Rybak, M.J.6
  • 80
    • 84862532741 scopus 로고    scopus 로고
    • Efficacy of daptomycin-cloxacillin combination in experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus
    • Garrigós C.; Murillo O.; Lora-Tamayo J.; et al. Efficacy of daptomycin-cloxacillin combination in experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother: 2012; 56 7 3806 3811
    • (2012) Antimicrob Agents Chemother , vol.56 , Issue.7 , pp. 3806-3811
    • Garrigós, C.1    Murillo, O.2    Lora-Tamayo, J.3
  • 81
    • 79959722946 scopus 로고    scopus 로고
    • Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: Role of enhanced daptomycin binding
    • Dhand A.; Bayer A. S.; Pogliano J.; et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis: 2011; 53 2 158 163
    • (2011) Clin Infect Dis , vol.53 , Issue.2 , pp. 158-163
    • Dhand, A.1    Bayer, A.S.2    Pogliano, J.3
  • 82
    • 84908310810 scopus 로고    scopus 로고
    • Antimicrobial Salvage Therapy for Persistent Staphylococcal Bacteremia Using Daptomycin Plus Ceftaroline
    • Sakoulas G.; Moise P. A.; Casapao A. M.; et al. Antimicrobial Salvage Therapy for Persistent Staphylococcal Bacteremia Using Daptomycin Plus Ceftaroline. Clin Ther: 2014
    • (2014) Clin Ther
    • Sakoulas, G.1    Moise, P.A.2    Casapao, A.M.3
  • 83
    • 84890121651 scopus 로고    scopus 로고
    • Reduced glycopeptide and lipopeptide susceptibility in Staphylococcus aureus and the seesaw effect: Taking advantage of the back door left open
    • Ortwine J. K.; Werth B. J.; Sakoulas G.; Rybak M. J. Reduced glycopeptide and lipopeptide susceptibility in Staphylococcus aureus and the seesaw effect: Taking advantage of the back door left open? Drug Resist Updat: 2013; 16 3-5 73 79
    • (2013) Drug Resist Updat , vol.16 , Issue.35 , pp. 73-79
    • Ortwine, J.K.1    Werth, B.J.2    Sakoulas, G.3    Rybak, M.J.4
  • 85
    • 0033391363 scopus 로고    scopus 로고
    • Inactivation of the methicillin resistance gene mecA in vancomycin-resistant Staphylococcus aureus
    • Sieradzki K.; Wu S. W.; Tomasz A. Inactivation of the methicillin resistance gene mecA in vancomycin-resistant Staphylococcus aureus. Microb Drug Resist: 1999; 5 4 253 257
    • (1999) Microb Drug Resist , vol.5 , Issue.4 , pp. 253-257
    • Sieradzki, K.1    Wu, S.W.2    Tomasz, A.3
  • 86
    • 84894096216 scopus 로고    scopus 로고
    • Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus
    • Sakoulas G.; Okumura C. Y.; Thienphrapa W.; et al. Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus. J Mol Med (Berl): 2014; 92 2 139 149
    • (2014) J Mol Med (Berl) , vol.92 , Issue.2 , pp. 139-149
    • Sakoulas, G.1    Okumura, C.Y.2    Thienphrapa, W.3
  • 87
    • 0017861883 scopus 로고
    • In vitro activity of rifampin alone and in combination with nafcillin and Vancomycin against pathogenic strains of Staphylococcus aureus
    • Tuazon C. U.; Lin M. Y.; Sheagren J. N. In vitro activity of rifampin alone and in combination with nafcillin and Vancomycin against pathogenic strains of Staphylococcus aureus. Antimicrob Agents Chemother: 1978; 13 5 759 761
    • (1978) Antimicrob Agents Chemother , vol.13 , Issue.5 , pp. 759-761
    • Tuazon, C.U.1    Lin, M.Y.2    Sheagren, J.N.3
  • 88
    • 0030993180 scopus 로고    scopus 로고
    • In vitro activities of ciprofloxacin and rifampin alone and in combination against growing and nongrowing strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus
    • Bahl D.; Miller D. A.; Leviton I.; et al. In vitro activities of ciprofloxacin and rifampin alone and in combination against growing and nongrowing strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother: 1997; 41 6 1293 1297
    • (1997) Antimicrob Agents Chemother , vol.41 , Issue.6 , pp. 1293-1297
    • Bahl, D.1    Miller, D.A.2    Leviton, I.3
  • 89
    • 0015883143 scopus 로고
    • Interaction of intraleukocytic bacteria and antibiotics
    • Mandell G. L. Interaction of intraleukocytic bacteria and antibiotics. J Clin Invest: 1973; 52 7 1673 1679
    • (1973) J Clin Invest , vol.52 , Issue.7 , pp. 1673-1679
    • Mandell, G.L.1
  • 91
    • 29944444489 scopus 로고    scopus 로고
    • Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections
    • Saginur R.; Stdenis M.; Ferris W.; et al. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. Antimicrob Agents Chemother: 2006; 50 1 55 61
    • (2006) Antimicrob Agents Chemother , vol.50 , Issue.1 , pp. 55-61
    • Saginur, R.1    Stdenis, M.2    Ferris, W.3
  • 92
    • 42949142216 scopus 로고    scopus 로고
    • Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: A systematic review of the literature
    • Perlroth J.; Kuo M.; Tan J.; Bayer A. S.; Miller L. G. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med: 2008; 168 8 805 819
    • (2008) Arch Intern Med , vol.168 , Issue.8 , pp. 805-819
    • Perlroth, J.1    Kuo, M.2    Tan, J.3    Bayer, A.S.4    Miller, L.G.5
  • 93
    • 29044438266 scopus 로고    scopus 로고
    • Uptake, transport, delivery, and intracellular activity of antimicrobial agents
    • Mandell G. L. Uptake, transport, delivery, and intracellular activity of antimicrobial agents. Pharmacotherapy: 2005; 25 12, Pt 2 130S 133S
    • (2005) Pharmacotherapy , vol.25 , Issue.12 , pp. 130S-133S
    • Mandell, G.L.1
  • 94
    • 33644656768 scopus 로고    scopus 로고
    • Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages
    • Barcia-Macay M.; Seral C.; Mingeot-Leclercq M. P.; Tulkens P. M.; Van Bambeke F. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother: 2006; 50 3 841 851
    • (2006) Antimicrob Agents Chemother , vol.50 , Issue.3 , pp. 841-851
    • Barcia-Macay, M.1    Seral, C.2    Mingeot-Leclercq, M.P.3    Tulkens, P.M.4    Van Bambeke, F.5
  • 95
    • 0019458642 scopus 로고
    • Antistaphylococcal activity of rifampin with other antibiotics
    • Zinner S. H.; Lagast H.; Klastersky J. Antistaphylococcal activity of rifampin with other antibiotics. J Infect Dis: 1981; 144 4 365 371
    • (1981) J Infect Dis , vol.144 , Issue.4 , pp. 365-371
    • Zinner, S.H.1    Lagast, H.2    Klastersky, J.3
  • 96
    • 0020665582 scopus 로고
    • Treatment of experimental chronic osteomyelitis due to staphylococcus aureus with vancomycin and rifampin
    • Norden C. W.; Shaffer M. Treatment of experimental chronic osteomyelitis due to staphylococcus aureus with vancomycin and rifampin. J Infect Dis: 1983; 147 2 352 357
    • (1983) J Infect Dis , vol.147 , Issue.2 , pp. 352-357
    • Norden, C.W.1    Shaffer, M.2
  • 97
    • 0021159642 scopus 로고
    • Disparity between timed-kill and checkerboard methods for determination of in vitro bactericidal interactions of vancomycin plus rifampin versus methicillin-susceptible and -resistant Staphylococcus aureus
    • Bayer A. S.; Morrison J. O. Disparity between timed-kill and checkerboard methods for determination of in vitro bactericidal interactions of vancomycin plus rifampin versus methicillin-susceptible and -resistant Staphylococcus aureus. Antimicrob Agents Chemother: 1984; 26 2 220 223
    • (1984) Antimicrob Agents Chemother , vol.26 , Issue.2 , pp. 220-223
    • Bayer, A.S.1    Morrison, J.O.2
  • 98
    • 0021948514 scopus 로고
    • In vitro activities of rifapentine and rifampin, alone and in combination with six other antibiotics, against methicillin-susceptible and methicillin-resistant staphylococci of different species
    • Varaldo P. E.; Debbia E.; Schito G. C. In vitro activities of rifapentine and rifampin, alone and in combination with six other antibiotics, against methicillin-susceptible and methicillin-resistant staphylococci of different species. Antimicrob Agents Chemother: 1985; 27 4 615 618
    • (1985) Antimicrob Agents Chemother , vol.27 , Issue.4 , pp. 615-618
    • Varaldo, P.E.1    Debbia, E.2    Schito, G.C.3
  • 99
    • 0022637580 scopus 로고
    • Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus
    • Hackbarth C. J.; Chambers H. F.; Sande M. A. Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob Agents Chemother: 1986; 29 4 611 613
    • (1986) Antimicrob Agents Chemother , vol.29 , Issue.4 , pp. 611-613
    • Hackbarth, C.J.1    Chambers, H.F.2    Sande, M.A.3
  • 100
    • 0022631448 scopus 로고
    • Novobiocin and rifampicin in combination against methicillin-resistant Staphylococcus aureus: An in-vitro comparison with vancomycin plus rifampicin
    • Walsh T. J.; Auger F.; Tatem B. A.; Hansen S. L.; Standiford H. C. Novobiocin and rifampicin in combination against methicillin-resistant Staphylococcus aureus: an in-vitro comparison with vancomycin plus rifampicin. J Antimicrob Chemother: 1986; 17 1 75 82
    • (1986) J Antimicrob Chemother , vol.17 , Issue.1 , pp. 75-82
    • Walsh, T.J.1    Auger, F.2    Tatem, B.A.3    Hansen, S.L.4    Standiford, H.C.5
  • 101
  • 102
    • 84885920711 scopus 로고    scopus 로고
    • In vitro efficacies and resistance profiles of rifampin-based combination regimens for biofilm-embedded methicillin-resistant Staphylococcus aureus
    • Tang H. J.; Chen C. C.; Cheng K. C.; et al. In vitro efficacies and resistance profiles of rifampin-based combination regimens for biofilm-embedded methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother: 2013; 57 11 5717 5720
    • (2013) Antimicrob Agents Chemother , vol.57 , Issue.11 , pp. 5717-5720
    • Tang, H.J.1    Chen, C.C.2    Cheng, K.C.3
  • 103
    • 84884242692 scopus 로고    scopus 로고
    • Vancomycin-rifampin combination therapy has enhanced efficacy against an experimental Staphylococcus aureus prosthetic joint infection
    • Niska J. A.; Shahbazian J. H.; Ramos R. I.; Francis K. P.; Bernthal N. M.; Miller L. S. Vancomycin-rifampin combination therapy has enhanced efficacy against an experimental Staphylococcus aureus prosthetic joint infection. Antimicrob Agents Chemother: 2013; 57 10 5080 5086
    • (2013) Antimicrob Agents Chemother , vol.57 , Issue.10 , pp. 5080-5086
    • Niska, J.A.1    Shahbazian, J.H.2    Ramos, R.I.3    Francis, K.P.4    Bernthal, N.M.5    Miller, L.S.6
  • 104
    • 0023612971 scopus 로고
    • Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin
    • (4A)
    • Henry N. K.; Rouse M. S.; Whitesell A. L.; McConnell M. E.; Wilson W. R. Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin. Am J Med: 1987; 82 (4A): 73 75
    • (1987) Am J Med , vol.82 , pp. 73-75
    • Henry, N.K.1    Rouse, M.S.2    Whitesell, A.L.3    McConnell, M.E.4    Wilson, W.R.5
  • 105
    • 0028231918 scopus 로고
    • Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus
    • Zimmerli W.; Frei R.; Widmer A. F.; Rajacic Z. Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J Antimicrob Chemother: 1994; 33 5 959 967
    • (1994) J Antimicrob Chemother , vol.33 , Issue.5 , pp. 959-967
    • Zimmerli, W.1    Frei, R.2    Widmer, A.F.3    Rajacic, Z.4
  • 106
    • 0026046834 scopus 로고
    • Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations
    • Chuard C.; Herrmann M.; Vaudaux P.; Waldvogel F. A.; Lew D. P. Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations. Antimicrob Agents Chemother: 1991; 35 12 2611 2616
    • (1991) Antimicrob Agents Chemother , vol.35 , Issue.12 , pp. 2611-2616
    • Chuard, C.1    Herrmann, M.2    Vaudaux, P.3    Waldvogel, F.A.4    Lew, D.P.5
  • 107
    • 0021970336 scopus 로고
    • Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: In vitro-in vivo correlations
    • Bayer A. S.; Lam K. Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations. J Infect Dis: 1985; 151 1 157 165
    • (1985) J Infect Dis , vol.151 , Issue.1 , pp. 157-165
    • Bayer, A.S.1    Lam, K.2
  • 108
    • 0025279741 scopus 로고
    • Oral temafloxacin versus vancomycin for therapy of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus
    • Hessen M. T.; Pitsakis P. G.; Kaye D. Oral temafloxacin versus vancomycin for therapy of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother: 1990; 34 6 1143 1145
    • (1990) Antimicrob Agents Chemother , vol.34 , Issue.6 , pp. 1143-1145
    • Hessen, M.T.1    Pitsakis, P.G.2    Kaye, D.3
  • 109
    • 0029155377 scopus 로고
    • Vancomycin or vancomycin plus netilmicin for methicillin- and gentamicin-resistant Staphylococcus aureus aortic valve experimental endocarditis
    • Perdikaris G.; Giamarellou H.; Pefanis A.; Donta I.; Karayiannakos P. Vancomycin or vancomycin plus netilmicin for methicillin- and gentamicin-resistant Staphylococcus aureus aortic valve experimental endocarditis. Antimicrob Agents Chemother: 1995; 39 10 2289 2294
    • (1995) Antimicrob Agents Chemother , vol.39 , Issue.10 , pp. 2289-2294
    • Perdikaris, G.1    Giamarellou, H.2    Pefanis, A.3    Donta, I.4    Karayiannakos, P.5
  • 110
    • 0026047842 scopus 로고
    • Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis
    • Levine D. P.; Fromm B. S.; Reddy B. R. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med: 1991; 115 9 674 680
    • (1991) Ann Intern Med , vol.115 , Issue.9 , pp. 674-680
    • Levine, D.P.1    Fromm, B.S.2    Reddy, B.R.3
  • 111
    • 46249111351 scopus 로고    scopus 로고
    • Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus
    • Riedel D. J.; Weekes E.; Forrest G. N. Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus. Antimicrob Agents Chemother: 2008; 52 7 2463 2467
    • (2008) Antimicrob Agents Chemother , vol.52 , Issue.7 , pp. 2463-2467
    • Riedel, D.J.1    Weekes, E.2    Forrest, G.N.3
  • 112
    • 74049140267 scopus 로고    scopus 로고
    • Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia
    • Jung Y. J.; Koh Y.; Hong S. B.; et al. Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Crit Care Med: 2010; 38 1 175 180
    • (2010) Crit Care Med , vol.38 , Issue.1 , pp. 175-180
    • Jung, Y.J.1    Koh, Y.2    Hong, S.B.3
  • 113
    • 84871173867 scopus 로고    scopus 로고
    • Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST): Study protocol for a randomised controlled trial
    • United Kingdom Clinical Infection Research Group
    • Thwaites G.; Auckland C.; Barlow G.; et al. United Kingdom Clinical Infection Research Group. Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST): study protocol for a randomised controlled trial. Trials: 2012; 13 241
    • (2012) Trials , vol.13 , pp. 241
    • Thwaites, G.1    Auckland, C.2    Barlow, G.3
  • 114
    • 0022357174 scopus 로고
    • Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections
    • Auwera Van der P.; Klastersky J.; Thys J. P.; Meunier-Carpentier F.; Legrand J. C. Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections. Antimicrob Agents Chemother: 1985; 28 4 467 472
    • (1985) Antimicrob Agents Chemother , vol.28 , Issue.4 , pp. 467-472
    • Auwera Van Der, P.1    Klastersky, J.2    Thys, J.P.3    Meunier-Carpentier, F.4    Legrand, J.C.5
  • 115
    • 0020788601 scopus 로고
    • Clinical study of combination therapy with oxacillin and rifampin for staphylococcal infections
    • (Suppl 3)
    • Van der Auwera P.; Meunier-Carpentier F.; Klastersky J. Clinical study of combination therapy with oxacillin and rifampin for staphylococcal infections. Rev Infect Dis: 1983; 5 (Suppl 3): S515 S522
    • (1983) Rev Infect Dis , vol.5 , pp. S515-S522
    • Van Der Auwera, P.1    Meunier-Carpentier, F.2    Klastersky, J.3
  • 116
    • 84858635387 scopus 로고    scopus 로고
    • Mandatory surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in England: The first 10 years
    • Johnson A. P.; Davies J.; Guy R.; et al. Mandatory surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in England: the first 10 years. J Antimicrob Chemother: 2012; 67 4 802 809
    • (2012) J Antimicrob Chemother , vol.67 , Issue.4 , pp. 802-809
    • Johnson, A.P.1    Davies, J.2    Guy, R.3
  • 117
    • 84872017969 scopus 로고    scopus 로고
    • Outcome of debridement and retention in prosthetic joint infections by methicillin-resistant staphylococci, with special reference to rifampin and fusidic acid combination therapy
    • Peel T. N.; Buising K. L.; Dowsey M. M.; et al. Outcome of debridement and retention in prosthetic joint infections by methicillin-resistant staphylococci, with special reference to rifampin and fusidic acid combination therapy. Antimicrob Agents Chemother: 2013; 57 1 350 355
    • (2013) Antimicrob Agents Chemother , vol.57 , Issue.1 , pp. 350-355
    • Peel, T.N.1    Buising, K.L.2    Dowsey, M.M.3
  • 118
    • 34248365254 scopus 로고    scopus 로고
    • Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid
    • Aboltins C. A.; Page M. A.; Buising K. L.; et al. Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid. Clin Microbiol Infect: 2007; 13 6 586 591
    • (2007) Clin Microbiol Infect , vol.13 , Issue.6 , pp. 586-591
    • Aboltins, C.A.1    Page, M.A.2    Buising, K.L.3
  • 119
    • 0032550664 scopus 로고    scopus 로고
    • Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: A randomized controlled trial
    • Zimmerli W.; Widmer A. F.; Blatter M.; Frei R.; Ochsner P. E. Foreign-Body Infection (FBI) Study Group Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. JAMA: 1998; 279 19 1537 1541
    • (1998) JAMA , vol.279 , Issue.19 , pp. 1537-1541
    • Zimmerli, W.1    Widmer, A.F.2    Blatter, M.3    Frei, R.4    Ochsner, P.E.5
  • 120
    • 79961244780 scopus 로고    scopus 로고
    • Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to Staphylococcus aureus
    • Senneville E.; Joulie D.; Legout L.; et al. Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to Staphylococcus aureus. Clin Infect Dis: 2011; 53 4 334 340
    • (2011) Clin Infect Dis , vol.53 , Issue.4 , pp. 334-340
    • Senneville, E.1    Joulie, D.2    Legout, L.3
  • 121
    • 77955471874 scopus 로고    scopus 로고
    • Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention
    • El Helou O. C.; Berbari E. F.; Lahr B. D.; et al. Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention. Eur J Clin Microbiol Infect Dis: 2010; 29 8 961 967
    • (2010) Eur J Clin Microbiol Infect Dis , vol.29 , Issue.8 , pp. 961-967
    • El Helou, O.C.1    Berbari, E.F.2    Lahr, B.D.3
  • 122
    • 84871804102 scopus 로고    scopus 로고
    • A large multicenter study of methicillin-susceptible and methicillin-resistant Staphylococcus aureus prosthetic joint infections managed with implant retention
    • REIPI Group for the Study of Prosthetic Infection
    • Lora-Tamayo J.; Murillo O.; Iribarren J. A.; et al. REIPI Group for the Study of Prosthetic Infection. A large multicenter study of methicillin-susceptible and methicillin-resistant Staphylococcus aureus prosthetic joint infections managed with implant retention. Clin Infect Dis: 2013; 56 2 182 194
    • (2013) Clin Infect Dis , vol.56 , Issue.2 , pp. 182-194
    • Lora-Tamayo, J.1    Murillo, O.2    Iribarren, J.A.3
  • 123
    • 84878840687 scopus 로고    scopus 로고
    • Recommendations for rifampicin therapy of staphylococcal infection in Infectious Diseases Society of America prosthetic Joint Infection Guidelines are not supported by available literature
    • Eisen D. P.; Denholm J. S. Recommendations for rifampicin therapy of staphylococcal infection in Infectious Diseases Society of America prosthetic Joint Infection Guidelines are not supported by available literature. Clin Infect Dis: 2013; 57 1 159 160
    • (2013) Clin Infect Dis , vol.57 , Issue.1 , pp. 159-160
    • Eisen, D.P.1    Denholm, J.S.2
  • 124
    • 84871247727 scopus 로고    scopus 로고
    • Executive summary: Diagnosis and management of prosthetic joint infection: Clinical practice guidelines by the Infectious Diseases Society of America
    • Infectious Diseases Society of America
    • Osmon D. R.; Berbari E. F.; Berendt A. R.; et al. Infectious Diseases Society of America. Executive summary: diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis: 2013; 56 1 1 10
    • (2013) Clin Infect Dis , vol.56 , Issue.1 , pp. 1-10
    • Osmon, D.R.1    Berbari, E.F.2    Berendt, A.R.3
  • 125
    • 70349300536 scopus 로고    scopus 로고
    • Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis
    • LaPlante K. L.; Woodmansee S. Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis. Antimicrob Agents Chemother: 2009; 53 9 3880 3886
    • (2009) Antimicrob Agents Chemother , vol.53 , Issue.9 , pp. 3880-3886
    • Laplante, K.L.1    Woodmansee, S.2
  • 126
    • 70349485395 scopus 로고    scopus 로고
    • Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus
    • Hospital Clinic Experimental Endocarditis Study Group
    • Miró J. M.; García-de-la-Mària C.; Armero Y.; et al. Hospital Clinic Experimental Endocarditis Study Group. Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother: 2009; 53 10 4172 4177
    • (2009) Antimicrob Agents Chemother , vol.53 , Issue.10 , pp. 4172-4177
    • Miró, J.M.1    García-De-La-Mària, C.2    Armero, Y.3
  • 127
    • 84879015914 scopus 로고    scopus 로고
    • Relationship of in vitro synergy and treatment outcome with daptomycin plus rifampin in patients with invasive methicillin-resistant Staphylococcus aureus infections
    • Rose W. E.; Berti A. D.; Hatch J. B.; Maki D. G. Relationship of in vitro synergy and treatment outcome with daptomycin plus rifampin in patients with invasive methicillin-resistant Staphylococcus aureus infections. Antimicrob Agents Chemother: 2013; 57 7 3450 3452
    • (2013) Antimicrob Agents Chemother , vol.57 , Issue.7 , pp. 3450-3452
    • Rose, W.E.1    Berti, A.D.2    Hatch, J.B.3    Maki, D.G.4
  • 128
    • 84879418076 scopus 로고    scopus 로고
    • The safety and efficacy of high-dose daptomycin combined with rifampicin for the treatment of Gram-positive osteoarticular infections
    • Jugun K.; Vaudaux P.; Garbino J.; et al. The safety and efficacy of high-dose daptomycin combined with rifampicin for the treatment of Gram-positive osteoarticular infections. Int Orthop: 2013; 37 7 1375 1380
    • (2013) Int Orthop , vol.37 , Issue.7 , pp. 1375-1380
    • Jugun, K.1    Vaudaux, P.2    Garbino, J.3
  • 129
    • 84926180165 scopus 로고    scopus 로고
    • High doses of daptomycin (10 mg/kg/d) plus rifampin for the treatment of staphylococcal prosthetic joint infection managed with implant retention: A comparative study
    • Lora-Tamayo J.; Parra-Ruiz J.; Rodríguez-Pardo D.; et al. High doses of daptomycin (10 mg/kg/d) plus rifampin for the treatment of staphylococcal prosthetic joint infection managed with implant retention: a comparative study. Diagn Microbiol Infect Dis: 2014; 80 1 66 71
    • (2014) Diagn Microbiol Infect Dis , vol.80 , Issue.1 , pp. 66-71
    • Lora-Tamayo, J.1    Parra-Ruiz, J.2    Rodríguez-Pardo, D.3
  • 130
    • 0016225323 scopus 로고
    • Enhancement of the effects of anti-staphylococcal antibiotics by aminoglycosides
    • Watanakunakorm C.; Glotzbecker C. Enhancement of the effects of anti-staphylococcal antibiotics by aminoglycosides. Antimicrob Agents Chemother: 1974; 6 6 802 806
    • (1974) Antimicrob Agents Chemother , vol.6 , Issue.6 , pp. 802-806
    • Watanakunakorm, C.1    Glotzbecker, C.2
  • 131
    • 0030685786 scopus 로고    scopus 로고
    • Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model
    • Houlihan H. H.; Mercier R. C.; Rybak M. J. Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model. Antimicrob Agents Chemother: 1997; 41 11 2497 2501
    • (1997) Antimicrob Agents Chemother , vol.41 , Issue.11 , pp. 2497-2501
    • Houlihan, H.H.1    Mercier, R.C.2    Rybak, M.J.3
  • 132
    • 82655173877 scopus 로고    scopus 로고
    • Combination therapy with an aminoglycoside for Staphylococcus aureus endocarditis and/or persistent bacteremia is associated with a decreased rate of recurrent bacteremia: A cohort study
    • Lemonovich T. L.; Haynes K.; Lautenbach E.; Amorosa V. K. Combination therapy with an aminoglycoside for Staphylococcus aureus endocarditis and/or persistent bacteremia is associated with a decreased rate of recurrent bacteremia: a cohort study. Infection: 2011; 39 6 549 554
    • (2011) Infection , vol.39 , Issue.6 , pp. 549-554
    • Lemonovich, T.L.1    Haynes, K.2    Lautenbach, E.3    Amorosa, V.K.4
  • 133
    • 62449226267 scopus 로고    scopus 로고
    • Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic
    • Cosgrove S. E.; Vigliani G. A.; Fowler V. G. Jr.; et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis: 2009; 48 6 713 721
    • (2009) Clin Infect Dis , vol.48 , Issue.6 , pp. 713-721
    • Cosgrove, S.E.1    Vigliani, G.A.2    Fowler, G.V.3
  • 134
    • 34247102790 scopus 로고    scopus 로고
    • Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus
    • Baltch A. L.; Ritz W. J.; Bopp L. H.; Michelsen P. B.; Smith R. P. Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus. Antimicrob Agents Chemother: 2007; 51 4 1559 1562
    • (2007) Antimicrob Agents Chemother , vol.51 , Issue.4 , pp. 1559-1562
    • Baltch, A.L.1    Ritz, W.J.2    Bopp, L.H.3    Michelsen, P.B.4    Smith, R.P.5
  • 135
    • 34247149253 scopus 로고    scopus 로고
    • Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology
    • Credito K.; Lin G.; Appelbaum P. C. Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology. Antimicrob Agents Chemother: 2007; 51 4 1504 1507
    • (2007) Antimicrob Agents Chemother , vol.51 , Issue.4 , pp. 1504-1507
    • Credito, K.1    Lin, G.2    Appelbaum, P.C.3
  • 136
    • 0023928340 scopus 로고
    • In vitro activity of LY146032 alone and in combination with other antibiotics against gram-positive bacteria
    • Debbia E.; Pesce A.; Schito G. C. In vitro activity of LY146032 alone and in combination with other antibiotics against gram-positive bacteria. Antimicrob Agents Chemother: 1988; 32 2 279 281
    • (1988) Antimicrob Agents Chemother , vol.32 , Issue.2 , pp. 279-281
    • Debbia, E.1    Pesce, A.2    Schito, G.C.3
  • 137
    • 9644255765 scopus 로고    scopus 로고
    • Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model
    • LaPlante K. L.; Rybak M. J. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother: 2004; 48 12 4665 4672
    • (2004) Antimicrob Agents Chemother , vol.48 , Issue.12 , pp. 4665-4672
    • Laplante, K.L.1    Rybak, M.J.2
  • 138
    • 33750587171 scopus 로고    scopus 로고
    • Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species
    • DeRyke C. A.; Sutherland C.; Zhang B.; Nicolau D. P.; Kuti J. L. Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species. Antimicrob Agents Chemother: 2006; 50 11 3529 3534
    • (2006) Antimicrob Agents Chemother , vol.50 , Issue.11 , pp. 3529-3534
    • Deryke, C.A.1    Sutherland, C.2    Zhang, B.3    Nicolau, D.P.4    Kuti, J.L.5
  • 139
    • 50949131109 scopus 로고    scopus 로고
    • Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations
    • Rose W. E.; Leonard S. N.; Rybak M. J. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother: 2008; 52 9 3061 3067
    • (2008) Antimicrob Agents Chemother , vol.52 , Issue.9 , pp. 3061-3067
    • Rose, W.E.1    Leonard, S.N.2    Rybak, M.J.3
  • 140
    • 42949139246 scopus 로고    scopus 로고
    • Activities of daptomycin and comparative antimicrobials, singly and in combination, against extracellular and intracellular Staphylococcus aureus and its stable small-colony variant in human monocyte-derived macrophages and in broth
    • Baltch A. L.; Ritz W. J.; Bopp L. H.; Michelsen P.; Smith R. P. Activities of daptomycin and comparative antimicrobials, singly and in combination, against extracellular and intracellular Staphylococcus aureus and its stable small-colony variant in human monocyte-derived macrophages and in broth. Antimicrob Agents Chemother: 2008; 52 5 1829 1833
    • (2008) Antimicrob Agents Chemother , vol.52 , Issue.5 , pp. 1829-1833
    • Baltch, A.L.1    Ritz, W.J.2    Bopp, L.H.3    Michelsen, P.4    Smith, R.P.5
  • 141
    • 84887538700 scopus 로고    scopus 로고
    • A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis
    • Kullar R.; Casapao A. M.; Davis S. L.; et al. A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. J Antimicrob Chemother: 2013; 68 12 2921 2926
    • (2013) J Antimicrob Chemother , vol.68 , Issue.12 , pp. 2921-2926
    • Kullar, R.1    Casapao, A.M.2    Davis, S.L.3
  • 142
    • 84868036029 scopus 로고    scopus 로고
    • Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations
    • Steed M. E.; Werth B. J.; Ireland C. E.; Rybak M. J. Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. Antimicrob Agents Chemother: 2012; 56 11 5709 5714
    • (2012) Antimicrob Agents Chemother , vol.56 , Issue.11 , pp. 5709-5714
    • Steed, M.E.1    Werth, B.J.2    Ireland, C.E.3    Rybak, M.J.4
  • 143
    • 84868014804 scopus 로고    scopus 로고
    • Daptomycin-nonsusceptible vancomycin-intermediate staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole
    • Avery L. M.; Steed M. E.; Woodruff A. E.; Hasan M.; Rybak M. J. Daptomycin-nonsusceptible vancomycin-intermediate staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother: 2012; 56 11 5990 5993
    • (2012) Antimicrob Agents Chemother , vol.56 , Issue.11 , pp. 5990-5993
    • Avery, L.M.1    Steed, M.E.2    Woodruff, A.E.3    Hasan, M.4    Rybak, M.J.5
  • 144
    • 84875597983 scopus 로고    scopus 로고
    • High dose of trimethoprim-sulfamethoxazole and daptomycin as a therapeutic option for MRSA endocarditis with large vegetation complicated by embolic stroke: A case report and literature review
    • Di Carlo P.; D'Alessandro N.; Guadagnino G.; et al. High dose of trimethoprim-sulfamethoxazole and daptomycin as a therapeutic option for MRSA endocarditis with large vegetation complicated by embolic stroke: a case report and literature review. Infez Med: 2013; 21 1 45 49
    • (2013) Infez Med , vol.21 , Issue.1 , pp. 45-49
    • Di Carlo, P.1    D'Alessandro, N.2    Guadagnino, G.3
  • 145
    • 40549092348 scopus 로고    scopus 로고
    • Effect of antibiotics, alone and in combination, on Panton-Valentine leukocidin production by a Staphylococcus aureus reference strain
    • Dumitrescu O.; Badiou C.; Bes M.; et al. Effect of antibiotics, alone and in combination, on Panton-Valentine leukocidin production by a Staphylococcus aureus reference strain. Clin Microbiol Infect: 2008; 14 4 384 388
    • (2008) Clin Microbiol Infect , vol.14 , Issue.4 , pp. 384-388
    • Dumitrescu, O.1    Badiou, C.2    Bes, M.3
  • 146
    • 34247114984 scopus 로고    scopus 로고
    • Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin
    • Dumitrescu O.; Boisset S.; Badiou C.; et al. Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin. Antimicrob Agents Chemother: 2007; 51 4 1515 1519
    • (2007) Antimicrob Agents Chemother , vol.51 , Issue.4 , pp. 1515-1519
    • Dumitrescu, O.1    Boisset, S.2    Badiou, C.3
  • 147
    • 84878576000 scopus 로고    scopus 로고
    • Effects of linezolid on suppressing in vivo production of staphylococcal toxins and improving survival outcomes in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia
    • Diep B. A.; Afasizheva A.; Le H. N.; et al. Effects of linezolid on suppressing in vivo production of staphylococcal toxins and improving survival outcomes in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia. J Infect Dis: 2013; 208 1 75 82
    • (2013) J Infect Dis , vol.208 , Issue.1 , pp. 75-82
    • Diep, B.A.1    Afasizheva, A.2    Le, H.N.3
  • 148
    • 77951820846 scopus 로고    scopus 로고
    • Prompt and successful toxin-targeting treatment of three patients with necrotizing pneumonia due to Staphylococcus aureus strains carrying the Panton-Valentine leukocidin genes
    • Rouzic N.; Janvier F.; Libert N.; et al. Prompt and successful toxin-targeting treatment of three patients with necrotizing pneumonia due to Staphylococcus aureus strains carrying the Panton-Valentine leukocidin genes. J Clin Microbiol: 2010; 48 5 1952 1955
    • (2010) J Clin Microbiol , vol.48 , Issue.5 , pp. 1952-1955
    • Rouzic, N.1    Janvier, F.2    Libert, N.3
  • 149
    • 79956135779 scopus 로고    scopus 로고
    • Factors associated with the outcome of life-threatening necrotizing pneumonia due to community-acquired Staphylococcus aureus in adult and adolescent patients
    • Li H. T.; Zhang T. T.; Huang J.; Zhou Y. Q.; Zhu J. X.; Wu B. Q. Factors associated with the outcome of life-threatening necrotizing pneumonia due to community-acquired Staphylococcus aureus in adult and adolescent patients. Respiration: 2011; 81 6 448 460
    • (2011) Respiration , vol.81 , Issue.6 , pp. 448-460
    • Li, H.T.1    Zhang, T.T.2    Huang, J.3    Zhou, Y.Q.4    Zhu, J.X.5    Wu, B.Q.6
  • 151
    • 80255133208 scopus 로고    scopus 로고
    • Pragmatic management of Panton-Valentine leukocidin-associated staphylococcal diseases
    • Gillet Y.; Dumitrescu O.; Tristan A.; et al. Pragmatic management of Panton-Valentine leukocidin-associated staphylococcal diseases. Int J Antimicrob Agents: 2011; 38 6 457 464
    • (2011) Int J Antimicrob Agents , vol.38 , Issue.6 , pp. 457-464
    • Gillet, Y.1    Dumitrescu, O.2    Tristan, A.3
  • 153
    • 84907260952 scopus 로고    scopus 로고
    • Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents
    • Lin G.; Pankuch G.; Appelbaum P. C.; Kosowska-Shick K. Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents. Antimicrob Agents Chemother: 2014; 58 10 6251 6254
    • (2014) Antimicrob Agents Chemother , vol.58 , Issue.10 , pp. 6251-6254
    • Lin, G.1    Pankuch, G.2    Appelbaum, P.C.3    Kosowska-Shick, K.4
  • 154
    • 77951221511 scopus 로고    scopus 로고
    • Antistaphylococcal activities of telavancin tested alone and in combination by time-kill assay
    • Lin G.; Pankuch G. A.; Ednie L. M.; Appelbaum P. C. Antistaphylococcal activities of telavancin tested alone and in combination by time-kill assay. Antimicrob Agents Chemother: 2010; 54 5 2201 2205
    • (2010) Antimicrob Agents Chemother , vol.54 , Issue.5 , pp. 2201-2205
    • Lin, G.1    Pankuch, G.A.2    Ednie, L.M.3    Appelbaum, P.C.4
  • 155
    • 84901479100 scopus 로고    scopus 로고
    • In vitro activity of fosfomycin in combination with linezolid against clinical isolates of methicillin-resistant Staphylococcus aureus
    • Xu-hong Y.; Falagas M. E.; Dong W.; Karageorgopoulos D. E.; De-feng L.; Rui W. In vitro activity of fosfomycin in combination with linezolid against clinical isolates of methicillin-resistant Staphylococcus aureus. J Antibiot (Tokyo): 2014; 67 5 369 371
    • (2014) J Antibiot (Tokyo) , vol.67 , Issue.5 , pp. 369-371
    • Xu-Hong, Y.1    Falagas, M.E.2    Dong, W.3    Karageorgopoulos, D.E.4    De-Feng, L.5    Rui, W.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.